



ASX ANNOUNCEMENT

6 June 2024

Opyl Announces First Trial Gen Revenue and Inaugural Customer: Brain Vector

Melbourne, Australia – Opyl Limited (ASX: OPL or “the Company”), a leading provider of AI-driven clinical trial design and optimisation solutions, today announces the first revenue from its recently launched TrialGen platform. Inaugural customer, Brain Vector is a pioneering company in personalised mental healthcare.

Key Highlights:

- TrialKey has secured its first contract with Brain Vector, a pioneering company in personalised mental healthcare.
- TrialKey will support Brain Vector across 4 of its services: Competitor Analysis, Trial Design Optimisation, Probability of Success Analysis Simulation, Reporting.
- Total contract value is up to A\$30,000 to be delivered over the term of A\$5,000 per trial across up to 6 total trials. TrialKey is sharing the risk with Brain Vector, if they don't get their next round of funding, they will not have an obligation to pay this fee.
- The partnership underscores Opyl's commitment to leveraging AI technology to transform clinical research and improve patient outcomes.

Significance for Opyl

This engagement with Brain Vector marks a significant milestone for Opyl, as it validates the value and effectiveness of our recently launched TrialGen platform in real-world clinical settings. By providing data-driven insights and optimisation strategies, we aim to enhance the success rates of clinical trials and support the development of groundbreaking therapies.

The total contract value for Opyl is up to A\$30,000 and spans across 4 services:

- Competitor Analysis
- Trial Design Optimisation based on real-world evidence
- Probability of Success Analysis Simulation
- Trials to be analysed, designed, optimised, simulated, and two reports generated each for 6 trials.



In the event that a Brain Vector trial does not receive funding, then Brain Vector shall have no payment obligation of A\$5,000 as part of the total A\$30,000 contract.

The partnership also underscores our commitment to leveraging AI technology to transform clinical research and improve patient outcomes.

Opyl's Role and Services

Brain Vector will be using TrialGen to support protocol design and provide competitor analysis to support their real-world evidence trial using VRPME™ as a non-regulated companion tool for psychologists. Our comprehensive services include:

1. **Competitor Analysis:**
 - Identifying competitor trials using Brain Vector technology or related therapies.
 - Conducting in-depth analysis of technology usage, methodologies, and outcomes of identified trials.

2. **Trial Design Generation:**
 - Drafting a comprehensive trial design to enhance success probabilities based on TrialGen's recommendations.
 - Including detailed protocols, arms, and criteria for participant inclusion/exclusion.
 - Defining primary and secondary endpoints.
 - Identifying optimal countries/sites for trial execution.

3. **Probability of Success Analysis Simulation:**
 - Utilising TrialGen for simulation and estimation of success probabilities.
 - Presenting probability distributions to illustrate potential trial outcomes.
 - Conducting sensitivity analysis to identify critical factors affecting success likelihood.

These services will be detailed in two reports: an investor-focused report and a more detailed clinical-focused version.

Opyl Executive Chairman Saurabh Jain said: *"Our partnership with Brain Vector marks a significant milestone with the first revenue generated from the TrialGen platform. This collaboration underscores the immense potential and transformative impact of our AI-driven clinical trial solutions in real-world settings. By joining forces with Brain Vector, a leader in personalised mental healthcare, we are poised to drive groundbreaking advancements in mental health therapies. This partnership not only validates our innovative approach but also opens considerable future opportunities to enhance the success rates of clinical trials and improve patient outcomes globally. We look forward to leveraging our combined expertise to transform the landscape of mental health care."*



Brain Vector CEO Dr. Stephane Verhaeghe said: *"The integration of Opyl's AI-driven TrialGen platform into our clinical trial processes represents a significant step forward in our mission to revolutionise mental health therapies. By leveraging Opyl's expertise in clinical trial design and optimisation, we aim to enhance the efficacy and success rates of our innovative VRPME™ technology. This collaboration opens up substantial opportunities for both companies to make a lasting impact on mental health treatment and improve the quality of life for countless individuals."*

About Brain Vector

Brain Vector is a unique approach for mental health therapy with its proprietary technology, VRPME™ (Virtual Reality Positive Memory Enhancement). This cutting-edge approach promotes brain homeostasis and psychological well-being by helping patients relive positive experiences tailored to their unique life journeys. Brain Vector's VRPME™ is developing a precision therapy designed to minimise the development of mental health conditions and optimise mental performance across various fields.

This announcement has been authorised for release by the board.

-ENDS-

For general enquiries:

Email: info@opyl.ai

Website: www.opyl.ai

For investor enquiries:

Bernice Averion

Head of Marketing and Communications

Phone: +61 415 311 957

Email: bernice.averion@opyl.ai

About Opyl Limited (ASX: OPL)

Opyl Limited is an AI company dedicated to leveraging data and technology to transform the landscape of clinical trials and medical research. With a commitment to innovation and strategic growth, Opyl is positioned to lead the way in shaping the future of healthcare solutions.